ClinicalTrials.gg
RecruitingNCT07660913Updated Jul 8, 2026

Effectiveness of Matrix Rhythm Therapy on Carpal Tunnel Syndrome

An interventional study of Matrix Rhythm Therapy and Sham Matrix Rhythm Therapy in Carpal Tunnel Syndrome, sponsored by Izmir Bakircay University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-07-08.

Sponsored by Izmir Bakircay University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 130 studies in Carpal Tunnel Syndrome with a site in Turkey — 36 open to participants now, 41 under way, none of them phase 3. Carpal Tunnel Syndrome · Turkey.

Planned enrollment
20th of 82
84 · median 60
Started
2026
with 19 others
No phase
75 of 130
21 open now
Primary completion
2027-07
later than 36 of 40 live
Registered
119th of 130
by date

Among the 130 studies in Carpal Tunnel Syndrome with a site in Turkey, this one is the 20th largest by planned enrollment of the 82 interventional ones that give a count, is one of 20 that started in 2026, is one of 75 with no phase, reaches primary completion later than 36 of the 40 other live ones, and was the 119th registered.

Carpal Tunnel Syndrome

591 studies on the registry are indexed under Carpal Tunnel Syndrome; 133 are open to participants now.

Browse Carpal Tunnel Syndrome studies →

Open to participants now

36 of the 130 studies in Carpal Tunnel Syndrome with a site in Turkey are open now. Recruiting first, the newest first:

30 more — sign in →

All 36 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 72 Carpal Tunnel Syndrome studies recruiting now, 27 (38%) set no upper age limit and 36 (50%) stop at 75 or younger; 1 takes children under 18; 11 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 130 studies in Carpal Tunnel Syndrome with a site in Turkey, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the effects of matrix rhythm therapy, applied in addition to conventional treatment, on symptom severity, function, grip and pinch strength, and quality of life in patients with carpal tunnel syndrome.

03

Conditions studied

  • Carpal Tunnel Syndrome
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Having a diagnosis of unilateral carpal tunnel syndrome confirmed by an orthopedist based on clinical examination and electromyography (EMG) testing.
  • Being classified with mild-to-moderate carpal tunnel syndrome severity.
  • Having symptoms persisting for at least 12 weeks.
  • Having a (MMSE) score greater than 24.
  • Being literate (able to read and write).

Exclusion criteria

Exclusion Criteria:

  • History of prior carpal tunnel release surgery.
  • History of injection into the affected hand/wrist.
  • Having received physiotherapy for carpal tunnel syndrome within the last 6 months.
  • Presence of any neurological signs or symptoms in the upper extremity other than carpal tunnel syndrome.
  • History of prior surgery in the hand or wrist region due to other conditions.
  • Diagnosis of any systemic neurological disease.
  • Diagnosis of rheumatic diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus).
  • Having ongoing pain in the arm or hand due to any other underlying cause.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
84 participants (estimated)

Study arms

  • Experimental
    Matrix Rhythm Therapy Group

    This group will receive a conventional physiotherapy treatment combined with active matrix rhythm therapy.

    Device: Matrix Rhythm Therapy · Other: Conservative Physiotherapy

  • Sham comparator
    Sham Matrix Rhythm Therapy Group

    This group will receive a conventional physiotherapy treatment combined with a placebo application using the Hypervolt 2 Pro device.

    Device: Sham Matrix Rhythm Therapy · Other: Conservative Physiotherapy

Interventions

  • DeviceMatrix Rhythm Therapy

    Active matrix rhythm therapy applied for 40 minutes per session (10 min paraspinal muscles, 10 min over the flexor retinaculum, 10 min to extensor muscles, and 10 min to flexor muscles), 2 sessions per week for 6 weeks.

  • DeviceSham Matrix Rhythm Therapy

    Placebo application using the Hypervolt 2 Pro device for 40 minutes per session (10 min paraspinal, 10 min flexor retinaculum, 10 min extensors, 10 min flexors), 2 sessions per week for 6 weeks. It mimics the physical vibration and head shape of the matrix rhythm therapy device to maintain blinding.

  • OtherConservative Physiotherapy

    Participants use a night splint holding the wrist in neutral position. On clinic days, conservative physiotherapy sessions are administered immediately following the active or sham matrix rhythm therapy sessions, 2 days per week for 6 weeks. These supervised sessions include median nerve sliding exercises (3 sets, 5 reps) and passive stretching for wrist flexors/extensors (15-sec hold, 3 sets, 5 reps). In addition to clinical sessions, the same exercise protocol is performed at home twice daily and continued independently up to the 12th-week follow-up. Compliance with both splint wear and home exercises is strictly monitored using participant usage logs and exercise diaries.

06

What researchers measure

Primary outcomes

  1. Change from Baseline in the Boston Carpal Tunnel Questionnaire - Symptom Severity Scale at 6 and 12 Weeks

    This scale evaluates the severity of symptoms including pain, numbness, and paresthesia over the past two weeks. It consists of 11 items, each scored on a Likert scale from 1 (no symptoms) to 5 (most severe symptoms). The total score is calculated by dividing the sum of individual item scores by 11. Final scores range from 1 to 5, where higher scores indicate greater symptom severity.

    Time frame: Baseline, Post-treatment (Week 6), and Follow-up (Week 12)

  2. Change from Baseline in the Boston Carpal Tunnel Questionnaire - Functional Status Scale at 6 and 12 Weeks

    This scale assesses hand-related functional limitations during daily activities. It consists of 8 items, each scored on a Likert scale from 1 (no difficulty) to 5 (cannot perform activity at all). The total score is calculated by dividing the sum of individual item scores by 8. Final scores range from 1 to 5, where higher scores indicate greater functional impairment.

    Time frame: Baseline, Post-treatment (Week 6), and Follow-up (Week 12)

Secondary outcomes

  1. Change from Baseline in Hand Grip Strength at 6 and 12 Weeks

    Measured using a hand dynamometer. The participant is seated with the shoulder adducted at 0 degrees, elbow flexed at 90 degrees, and forearm/wrist in neutral position. The measurement will be repeated three times for the affected hand with 5-second intervals, and the arithmetic mean will be recorded. Higher values indicate greater grip strength measured in kilograms (kg).

    Time frame: Baseline, Post-treatment (Week 6), and Follow-up (Week 12)

  2. Change from Baseline in Pinch Strength at 6 and 12 Weeks

    Assessed using a pinch gauge to measure tip pinch strength. The participant is seated with the shoulder adducted at 0 degrees, elbow flexed at 90 degrees, and forearm/wrist in neutral position, and asked to squeeze the device with maximum effort using the tips of the thumb and index finger. The measurement will be repeated three times for the affected hand with 5-second intervals, and the arithmetic mean will be recorded. Higher values indicate greater pinch strength measured in kilograms (kg).

    Time frame: Baseline, Post-treatment (Week 6), and Follow-up (Week 12)

  3. Change from Baseline in the EQ-5D-5L Index Score at 6 and 12 Weeks

    Evaluated using the EuroQol (EQ-5D-5L) scale, which covers 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 response levels. These responses are converted into a single health-state index score using the country-specific value set. Index scores typically range from less than 0 to 1, where higher scores indicate a better health-related quality of life.

    Time frame: Baseline, Post-treatment (Week 6), and Follow-up (Week 12)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Jul 2027, 12 months after the start.

Of 252 non-industry interventional studies with no phase under Carpal Tunnel Syndrome, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 27. This study's planned 12 months is close to that.

Counting every sponsor, half of 262 studies reached it within 12 months; a quarter within 7 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2026
First posted
Jun 22, 2026
StartActual
Jul 1, 2026
Primary completionEst.
Jul 1, 2027
CompletionEst.
Sep 1, 2027
Last update
Jul 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07660913
Lead sponsor
Izmir Bakircay University
Responsible party
Ertan Şahinoğlu, PhD (Assistant Professor, Izmir Bakircay University) — Principal investigator
First posted
Jun 22, 2026
Start date
Jul 1, 2026
Primary completion
Jul 1, 2027 (estimated)
Completion
Sep 1, 2027 (estimated)
Last update
Jul 8, 2026

Study contacts

Ertan Şahinoğlu, PhD
Contact
ertan.sahinoglu@bakircay.edu.tr
+90 232 493 00 00 ext. 14101
Ayşe Kayalı Vatansever, PhD
Contact
ayse.vatansever@bakircay.edu.tr
+90 232 493 00 00 ext. 14046

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion